For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Open Label | regadenoson: Subjects will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus). | None | None | 0 | 120 | 82 | 120 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| flushing | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| dyspnea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| chest discomf. | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| palpitations | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| abdominal discomfort | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| headache | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| dizziness | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| nausea | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| chest pain | SYSTEMATIC_ASSESSMENT | General disorders | None | View |